Guardant Health (GH) Osake Kurssi
Guardant Health Kurssi
Viimeisten 9 vuoden aikana Guardant Healthn liikevaihto kasvoi 52,3 % vuodessa ja ylsi 978,12 M USD:een. Guardant Healthn nettomarginaali −42,6 % on noussut verrattuna −109,3 %:iin muutama vuosi sitten. Guardant Healthn 12 kuukauden konsensustavoitehinta on 195,00 USD, noin yli kurssia 4,2 %. 35 analyytikosta 32 suosittaa ostoa — kokonaiskonsensus on Osta.
Guardant Health osakekurssi
Guardant Health liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Guardant Health -osakkeesta
The main competitors of Guardant Health Inc in the market include companies such as Foundation Medicine, Exact Sciences Corporation, and Illumina Inc.
The business model of Guardant Health Inc. revolves around precision oncology and liquid biopsy. As a leading precision oncology company, Guardant Health develops and commercializes blood tests that can detect and monitor cancer. By analyzing the genetic alterations in circulating tumor DNA, Guardant Health enables oncologists to make more informed treatment decisions for their patients. The company's comprehensive liquid biopsy platform, including their flagship product Guardant360, provides a non-invasive alternative to traditional tissue biopsies. With their commitment to advancing cancer care, Guardant Health Inc. aims to improve patient outcomes through their innovative molecular diagnostics and therapeutic development solutions.
Guardant Health Inc is primarily active in the healthcare industry.
Guardant Health Inc. is a leading precision oncology company specializing in blood-based cancer tests. Founded in 2012, Guardant Health has rapidly grown to become a prominent player in the field of liquid biopsy. The company's breakthrough technology, Guardant360, enables comprehensive genomic profiling of solid tumors through a simple blood draw, facilitating personalized treatment decisions for cancer patients. With an extensive database of over 120,000 patients, Guardant Health Inc. is revolutionizing cancer diagnostics and therapy selection. Guardant Health is committed to advancing precision oncology and improving patient outcomes through its innovative genomic testing solutions.
Some significant milestones achieved by Guardant Health Inc include the successful completion of their initial public offering (IPO) in October 2018, generating over $235 million in funding. Additionally, the company's liquid biopsy test, Guardant360, received breakthrough device designation from the U.S. FDA in 2018, highlighting its potential impact in cancer diagnostics. Guardant Health Inc also expanded its global presence by establishing partnerships with several pharmaceutical companies and collaborating with research institutions. These achievements demonstrate Guardant Health Inc's growth as a leader in precision oncology, offering innovative solutions and advancing cancer care.
Guardant Health Inc is primarily present in the United States.
Guardant Health Inc represents values of innovation, precision, and compassion in the field of comprehensive cancer care. As a leading precision oncology company, Guardant Health is committed to transforming cancer treatment through advanced diagnostics and therapeutics. With their liquid biopsy technology, they aim to provide personalized and non-invasive genomic profiling, aiding in early cancer detection and treatment decisions. Guardant Health's corporate philosophy revolves around collaboration and empowerment, as they strive to improve patient outcomes and ease the burden of cancer. By combining cutting-edge technology with compassionate care, Guardant Health Inc epitomizes a commitment to revolutionizing cancer care for a better future.
Analyytikot asettavat tällä hetkellä Guardant Health-osakkeelle keskimääräisen tavoitehinnan 188,80 USD (mediaani: 195,00 USD), mikä merkitsee +6,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 35 analyytikkoarvioon.
35 analyytikkoa arvioi tällä hetkellä Guardant Health-osaketta: 32 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Guardant Health-yhtiöltä 1,36 Mrd. USD liikevaihtoa ja −3,21 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Guardant Health-osake noteerataan hintaan 167,02 EUR (187,22 USD).
Guardant Health-osake (GH) on listattuna 5 pörssissä, muun muassa: NASDAQ (GH), XETRA (5GH.DE), Frankfurt (5GH.F), München (5GH.MU), Düsseldorf (5GH.DU).
Guardant Health Inc. is a leading company in the field of liquid biopsy and cancer early detection. The company offers innovative solutions and technologies for cancer prevention, diagnosis, and therapy. Guardant Health has two different business units: Guardant360 and GuardantOMNI. Both divisions differ in their target audience and product portfolio. Guardant360 is a blood test that captures the DNA profile of tumor cells, thereby identifying the genetic fingerprint of cancer cells. This allows for more precise and faster diagnosis. The technology of Guardant360 is used by doctors and oncologists to analyze the genetic profiles of tumor cells in real-time and develop the best possible therapy for the patient. GuardantOMNI is a comprehensive cancer genomic test that covers over 500 genes, enabling an accurate diagnosis. GuardantOMNI is used by pharmaceutical companies to develop personalized therapies and drugs. Guardant Health is committed to advancing precision medicine in the field of cancer diagnostics and therapy. By using liquid biopsy technologies, doctors and oncologists can make accurate diagnoses and offer targeted therapy. Guardant Health has also partnered with renowned pharmaceutical companies such as Merck, Bristol-Myers Squibb, and Amgen to develop personalized therapies. In addition, the company has conducted its own clinical study on cancer early detection, and further studies are planned. The business model of Guardant Health is based on selling its products and solutions to medical facilities such as hospitals, laboratories, and oncologists. The company also generates revenue through partnerships with pharmaceutical companies and participation in clinical trials. Overall, Guardant Health is a company with a promising business model based on the use of liquid biopsy technologies. The company aims to revolutionize cancer diagnostics and therapy and offer personalized medicine. The wide portfolio of solutions and products from Guardant Health allows it to cater to the needs of doctors, oncologists, and pharmaceutical companies.
odotettu liikevaihto Guardant Health on 1,36 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Guardant Health on −412,89 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Guardant Health:n hinta-voitto-suhde (P/E) on tällä hetkellä −58,34. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Guardant Health-osakkeen arvostusta.
Guardant Health:n hinta-myynti-suhde (P/S) on tällä hetkellä 17,74. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Guardant Health-osakkeen arvostuskennuslukuna.
Guardant Health:n Eulpool-laatuscore on 3/10.
Guardant Health:n ISIN on US40131M1099. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Guardant Health:n WKN on A2N5RY. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Guardant Health:n ticker on GH. Tämä pörssinoteeraus käytetään Guardant Health-osakkeiden kauppaan pörssissä.
Guardant Health osake
Guardant Health vertaisryhmä
Guardant Health Ticker
Guardant Health FIGI
Kaikki tunnusluvut ja syvällinen analyysi Guardant Health:sta
Meidän osakeanalyysimme Guardant Health-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Guardant Health:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: